NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer’s

  • The Company’s intellectual property now covers the combination, formulation, and method of use of PrimeC
  • Patent protection extends through 2042, adding four additional years to PrimeC’s IP umbrella

The newly granted patent, entitled “Compositions comprising Ciprofloxacin and Celecoxib” (US Patent No. US 12,097,185), relates to the novel formulation of PrimeC, NeuroSense’s leading drug candidate for the treatment of Amyotrophic Lateral Sclerosis (ALS). This patent is expected to extend PrimeC’s patent protection by an additional four years, until 2042.

Share:

Join Our Newsletter

Skip to content